Drug Profile


Alternative Names: hCDR1; TV-4710

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Teva Pharmaceutical Industries; XTL Biopharmaceuticals
  • Class Peptide fragments
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Sjogren's syndrome

Most Recent Events

  • 16 Jun 2017 Preclinical trials in Sjogren's syndrome in Israel (unspecified route)
  • 13 Feb 2017 XTL Biopharmaceuticals plans a phase II trial for Sjögren's syndrome
  • 05 Jan 2017 Early research in Sjogren's syndrome in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top